Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT00065351 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00065351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00065351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2003
Completion date
March 1, 2007
Enrollment
222 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma